Skip to main content
Journal cover image

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

Publication ,  Journal Article
Smeaton, LM; Kileel, EM; Grinsztejn, B; Gardner, EM; Starr, K; Murry, ML; Desvigne-Nickens, P; Alston-Smith, B; Waclawiw, MA; Cooper-Arnold, K ...
Published in: J Infect Dis
July 9, 2020

Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

July 9, 2020

Volume

222

Issue

Suppl 1

Start / End Page

S31 / S40

Location

United States

Related Subject Headings

  • Transsexualism
  • Sexual and Gender Minorities
  • Research Subjects
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Health Status
  • HIV Infections
  • Gender Identity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smeaton, L. M., Kileel, E. M., Grinsztejn, B., Gardner, E. M., Starr, K., Murry, M. L., … Klingman, K. L. (2020). Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis, 222(Suppl 1), S31–S40. https://doi.org/10.1093/infdis/jiaa213
Smeaton, Laura M., Emma M. Kileel, Beatriz Grinsztejn, Edward M. Gardner, Kate Starr, Melissa L. Murry, Patrice Desvigne-Nickens, et al. “Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.J Infect Dis 222, no. Suppl 1 (July 9, 2020): S31–40. https://doi.org/10.1093/infdis/jiaa213.
Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, et al. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 Jul 9;222(Suppl 1):S31–40.
Smeaton, Laura M., et al. “Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.J Infect Dis, vol. 222, no. Suppl 1, July 2020, pp. S31–40. Pubmed, doi:10.1093/infdis/jiaa213.
Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 Jul 9;222(Suppl 1):S31–S40.
Journal cover image

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

July 9, 2020

Volume

222

Issue

Suppl 1

Start / End Page

S31 / S40

Location

United States

Related Subject Headings

  • Transsexualism
  • Sexual and Gender Minorities
  • Research Subjects
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Health Status
  • HIV Infections
  • Gender Identity